AVITA Medical, Inc. (RCEL) Misses Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
BofA Securities Reiterates Buy Rating on Avita Medical Ltd. (RCEL)
May 14, 2024 8:48 AM EDTBofA Securities analyst Lyanne Harrison reiterated a Buy rating and $21.00 price target on Avita Medical Ltd. (NASDAQ: RCEL).
The analyst comments "We reiterate our Buy; PO unchanged at US$21/A$6. We expect AVITA will gain momentum as the year progresses, driven by short term... More
